Detalhe da pesquisa
1.
Antibiotic Use and Risk of Multiple Sclerosis: A Nested Case-Control Study in Emilia-Romagna Region, Italy.
Neuroepidemiology;
55(3): 224-231, 2021.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33965951
2.
Nabiximols discontinuation rate in a large population of patients with multiple sclerosis: a 18-month multicentre study.
J Neurol Neurosurg Psychiatry;
91(9): 914-920, 2020 09.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32661083
3.
Effects of THC/CBD oromucosal spray on spasticity-related symptoms in people with multiple sclerosis: results from a retrospective multicenter study.
Neurol Sci;
41(10): 2905-2913, 2020 Oct.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32335779
4.
Impact on Prehospital Delay of a Stroke Preparedness Campaign: A SW-RCT (Stepped-Wedge Cluster Randomized Controlled Trial).
Stroke;
48(12): 3316-3322, 2017 12.
Artigo
em Inglês
| MEDLINE
| ID: mdl-29101258
5.
Definitive childlessness in women with multiple sclerosis: a multicenter study.
Neurol Sci;
38(8): 1453-1459, 2017 Aug.
Artigo
em Inglês
| MEDLINE
| ID: mdl-28536948
6.
Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis.
Brain;
138(Pt 11): 3275-86, 2015 Nov.
Artigo
em Inglês
| MEDLINE
| ID: mdl-26362907
7.
First-line disease-modifying drugs in relapsing-remitting multiple sclerosis: an Italian real-life multicenter study on persistence.
Curr Med Res Opin;
34(10): 1803-1807, 2018 10.
Artigo
em Inglês
| MEDLINE
| ID: mdl-29526118
8.
Previous treatment influences fingolimod efficacy in relapsing-remitting multiple sclerosis: results from an observational study.
Curr Med Res Opin;
30(9): 1849-55, 2014 Sep.
Artigo
em Inglês
| MEDLINE
| ID: mdl-24831186